[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schistosomiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schistosomiasis":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,36,136,168,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":4},"100630018","prevalence-and-molecular-identification-of-human-schistosomiasis-100630018",false,"NCT07482215","Prevalence and Molecular Identification of Human Schistosomiasis","Prevalence and Molecular Identification of Human Schistosomiasis With Assessment of Associated Epidemiological Risk Factors in Assiut Governorate, Egypt","Inclusion Criteria:\n\n* Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.\n* Patients clinically suspected of having schistosomiasis (urinary and\u002For intestinal) or referred for parasitological examination.\n* Individuals (or guardians, in case of minors) who provide written informed consent.\n* Patients willing to provide the required biological samples (urine and\u002For stool).\n\nExclusion Criteria:\n\n* Patients Received praziquantel within the last 3 months before sample collection\n* Patients with incomplete clinical or epidemiological data.\n* Patients refusing participation or sample collection.\n* Improperly collected, contaminated, or insufficient samples.\n* Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).\n* children with congenital urinary or intestinal anomalies.","ALL",{"count":18,"type":19},359,"ESTIMATED","OBSERVATIONAL","Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma",[23],"Schistosomiasis","NOT_YET_RECRUITING","2026-03-16",{"date":27,"type":28},"2026-03-19","ACTUAL",{"date":30,"type":19},"2026-05",{"date":32,"type":19},"2027-12",{"name":34,"class":35},"Assiut University","OTHER",{"id":37,"slug":38,"hasResults":11,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":16,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":107,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"2 Years","75 Years",{"count":47,"type":19},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,23,105,106],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Streptococcus Pneumoniae","Meningitis",[108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":128,"type":28},"2026-01-22",{"date":130,"type":28},"2025-12-18",{"date":132,"type":19},"2027-09-30",{"name":134,"class":35},"Institut Pasteur du Cambodge",1,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":43,"sex":16,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100569766","introduction-of-arpraziquantel-treatment-for-schistosomiasis-control-in-preschool-aged-children-in-endemic-areas-a-small-scale-public-health-intervention-study-100569766","NCT06698510","Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study","Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Kenya and Côte d'Ivoire: A Small-scale Public Health Intervention Study Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Uganda, With Special Consideration of Dose Determination Methods: a Small-scale Public Health Intervention Study in Hoima and Bugiri Districts","ADOPTpilot","* Living in the designated implementation area since at least 6 months\n* Aged between 24 - 59 months\n* Informed consent available\n* No acute or chronic illness and\u002For inability to take oral medication\n* No reported history of seizures\n* No known allergic response to praziquantel","24 Months","59 Months",{"count":147,"type":19},18500,"The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ).\n\nThe aim of the small-scale pilot study is to assess the performance of different platforms for distributing arPZQ, a child-friendly formulation of praziquantel, to the target population (i.e., preschool-aged children (PSAC)) currently missed out in schistosomiasis treatment campaigns.\n\nThe specific objectives of the pilot study are:\n\n* To assess the performance of different platforms for delivery of arPZQ to PSAC aged 24 to 59 months in terms of coverage, feasibility and acceptability\n* To determine social mobilization and training needs for effective delivery of arPZQ through different platforms\n\nPreventive chemotherapy with arPZQ will be offered systematically to eligible PSAC aged 2 to below 5 years of consenting caregivers resident in the study area and reached through the selected platforms. Adverse events during MDA with arPZQ will be documented and reported by using existing tools and established reporting pathways aligned with standard pharmacovigilance and safety guidelines of the national drug authorities. Based on routine program processes and forms, variables pertaining to drug logistics, training, drug distribution, passive pharmacovigilance and supervision will be collected in order to measure and generate real-world data related to feasibility, coverage and acceptability of selected platforms and strategies to inform future scale-up to district levels.\n\nAssessments will take place before (to capture social mobilization and training activities) during and after the drug distribution to document the implementation process and evaluate experiences made by the different stakeholders (e.g. children, parents, community members, health workers, programme staff).",[23],[151,152,153,154,155,156,157],"schistosomiasis","preschool-aged children","praziquantel","arpraziquantel","deworming","pediatric treatment","child health","2025-09-19",{"date":160,"type":28},"2025-09-24",{"date":162,"type":28},"2024-11-25",{"date":164,"type":19},"2026-03",{"name":166,"class":35},"Peter Steinmann",7,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100583206","assessment-of-infection-activity-in-travelers-and-migrants-diagnosed-with-chronic-schistosomiasis-100583206","NCT06873308","Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis","Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis: a Multicentric Prospective Cohort Study","SchistAct","Inclusion criteria\n\n1. diagnosis of chronic schistosomiasis (\\>3 months after last potential exposure) according to site-specific diagnostic practice\n2. signed informed consent (and assent for minors).\n\nExclusion criteria\n\n1. age below 5 years;\n2. exposure to praziquantel after the last potential exposure to schistosomes\n3. acute infection, i.e. likely infection \\\u003C3 months before presentation","5 Years",{"count":178,"type":19},278,"INTERVENTIONAL",[181],"NA","The primary objective of this clinical investigation is to determine the percentage of travelers and migrants diagnosed with chronic schistosomiasis according to site-specific diagnostic practice who have active infection at the time of evaluation (as assessed and classified by composite reference standards that integrate clinical, laboratory, and diagnostic features, such as microscopy, PCR (where available), POC-CCA (where available), and serum CAA results).\n\nAll subjects with chronic schistosomiasis according to site-specific diagnostic practice will have a standardized baseline clinical and laboratory evaluation at the time of evaluation that will include blood sampling for hematology, schistosome serology available at each site, and schistosome PCR where available; urine sampling for microscopy, determination of hematuria as an indirect marker of morbidity for schistosomiasis, and Schistosome PCR (where available), and urine strip testing POC-CCA (where available); and stool sampling for microscopy and PCR, where available, and fecal occult blood as indirect markers of schistosomiasis morbidity.\n\nComposite reference standards will be used to assess and classify the activity of the infection. Organ-specific ultrasound and other tests will be left to the physician's decision, but results will also be collected.\n\nSerum (at least 1 ml remaining from routine diagnostics) will be sent to LUMC, the Netherlands, where CAA will be determined with the UCP-LF CAA test designed for routine use.\n\nParticipants will be asked to sign an additional consent form, which is optional and not precluding enrollment in the study, to allow the remaining serum to be stored at LUMC for 15 years, to allow secondary research.",[23],[151,185,186],"chronic","diagnosis","2025-04-16",{"date":189,"type":28},"2025-04-20",{"date":191,"type":28},"2024-06-28",{"date":193,"type":19},"2027-01",{"name":195,"class":35},"IRCCS Sacro Cuore Don Calabria di Negrar",8,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":204,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":179,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100579764","female-genital-schistosomiasis-in-migrant-women-a-pilot-study-100579764","NCT06828536","Female Genital Schistosomiasis in Migrant Women: A Pilot Study","GynoBizh","Inclusion Criteria:\n\n* Women aged 25 to 65 years\n* Born in a schistosomiasis-endemic area in sub-Saharan Africa\n* With a positive serology by Schistosoma spp. Western Blot\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patient unable to provide consent\n* Patient under guardianship or trusteeship\n* Patient who is a virgin at the time of selection\n* Patient who is pregnant at the time of selection","FEMALE","25 Years","65 Years",{"count":208,"type":19},50,[181],"This pilot study, \"GynoBizh,\" investigates the frequency and clinical characteristics of female genital schistosomiasis (FGS) among migrant women from sub-Saharan Africa living in non-endemic countries. Schistosomiasis is a significant global parasitic disease, with a high seroprevalence in migrants. The study aims to assess the presence of genital lesions through gynecological examinations, colposcopy, and molecular tests, identifying diagnostic markers and associated health conditions. Fifty participants will be followed over a year to improve understanding and management of FGS in underserved populations.",[212,23],"Diagnostic",[214,215,216,217,218],"femal genital schistosomiasis","migrant women","colposcopy","Diagnostic pilot study","Schistosoma spp. PCR","2025-02-10",{"date":221,"type":28},"2025-02-14",{"date":219,"type":19},{"date":224,"type":19},"2026-08-10",{"name":226,"class":35},"Assistance Publique - Hôpitaux de Paris"]